{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:37:05Z","timestamp":1792456625255,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.peptides.2024.171210","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:34:04Z","timestamp":1712190844000},"page":"171210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Targeting the GLP-2 receptor in the management of obesity"],"prefix":"10.1016","volume":"177","author":[{"given":"Thorir G.","family":"P\u00e1lsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Gilliam-Vigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.H.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle B.","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asger B.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper K.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2024.171210_bib1","unstructured":"T. Lobstein, R. Jackson-Leach, J. Powis, H. Brinsden, M. Gray, World Obesity Atlas 2023, World Obesity Federation (n.d.). \u3008https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2023\u3009 (accessed November 15, 2023)."},{"key":"10.1016\/j.peptides.2024.171210_bib2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1467-789X.2010.00766.x","article-title":"M & M: a mnemonic for assessing obesity","volume":"11","author":"Sharma","year":"2010","journal-title":"Obes. Rev."},{"key":"10.1016\/j.peptides.2024.171210_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.peptides.2024.171210_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies","volume":"67","author":"Luppino","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.peptides.2024.171210_bib5","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1053\/j.gastro.2006.03.019","article-title":"Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease","volume":"130","author":"Church","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2024.171210_bib6","first-page":"A48","article-title":"Prevalence of self-reported prediabetes among adults participating in a community-based health awareness program, New York State","volume":"6","author":"Hosler","year":"2009","journal-title":"Prev. Chronic Dis."},{"key":"10.1016\/j.peptides.2024.171210_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000350627","article-title":"Executive Committee of the European Association for the Study of Obesity, Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe","volume":"6","author":"Fr\u00fchbeck","year":"2013","journal-title":"Obes. Facts"},{"key":"10.1016\/j.peptides.2024.171210_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diabres.2014.04.006","article-title":"Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes","volume":"105","author":"Esser","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.peptides.2024.171210_bib9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Di Angelantonio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2024.171210_bib10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bluher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.peptides.2024.171210_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/obr.12551","article-title":"Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation","volume":"18","author":"Bray","year":"2017","journal-title":"Obes. Rev."},{"key":"10.1016\/j.peptides.2024.171210_bib12","first-page":"4","article-title":"Recent advances in the relationship between obesity, inflammation, and insulin resistance","volume":"17","author":"Bastard","year":"2006","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.peptides.2024.171210_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.peptides.2024.171210_bib14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/biom10020291","article-title":"Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications","volume":"10","author":"Kwaifa","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.peptides.2024.171210_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","article-title":"Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-\u03b1 and IL-6","volume":"69","author":"Park","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.peptides.2024.171210_bib16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/sj.ijo.0801792","article-title":"The relation of body fat mass and distribution to markers of chronic inflammation","volume":"25","author":"Festa","year":"2001","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2024.171210_bib17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/oby.2003.74","article-title":"Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression","volume":"11","author":"Bull\u00f3","year":"2003","journal-title":"Obes. Res."},{"key":"10.1016\/j.peptides.2024.171210_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41575-023-00766-3","article-title":"Paracellular permeability and tight junction regulation in gut health and disease","volume":"20","author":"Horowitz","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2024.171210_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41467-017-00900-1","article-title":"The gut microbiome in atherosclerotic cardiovascular disease","volume":"8","author":"Jie","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2024.171210_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.peptides.2024.171210_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program","volume":"31","author":"le Roux","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.peptides.2024.171210_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(23)01291-6","article-title":"CagriSema and the link between obesity and type 2 diabetes","volume":"402","author":"Apovian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2024.171210_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib24","unstructured":"C.K. Nielsen, Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial, clinicaltrials.gov, 2023. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05788601\u3009 (accessed January 1, 2023)."},{"key":"10.1016\/j.peptides.2024.171210_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.regpep.2013.03.025","article-title":"Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1 + GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study","volume":"184","author":"Madsen","year":"2013","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2024.171210_bib26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s12020-016-0871-3","article-title":"Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet","volume":"54","author":"Baldassano","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.peptides.2024.171210_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molmet.2018.06.006","article-title":"GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr\u2212\/\u2212 mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy","volume":"16","author":"Patel","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52103-x","article-title":"Metabolic and gut microbiome changes following GLP-1 or dual GLP-1\/GLP-2 receptor agonist treatment in diet-induced obese mice","volume":"9","author":"Madsen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.peptides.2024.171210_bib29","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/jpen.2307","article-title":"Complementary and antagonistic effects of combined glucagon-like peptide-2 and glucagon-like peptide-1 receptor agonist administration on parameters relevant to short bowel syndrome","volume":"46","author":"Srikrishnaraj","year":"2022","journal-title":"J. Parenter. Enter. Nutr."},{"key":"10.1016\/j.peptides.2024.171210_bib30","doi-asserted-by":"crossref","unstructured":"S. Tsalamandris, A.S. Antonopoulos, E. Oikonomou, G.-A. Papamikroulis, G. Vogiatzi, S. Papaioannou, S. Deftereos, D. Tousoulis, The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives, 14 (2019) 50\u201359. https:\/\/doi.org\/10.15420\/ecr.2018.33.1.","DOI":"10.15420\/ecr.2018.33.1"},{"key":"10.1016\/j.peptides.2024.171210_bib31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","article-title":"Metabolic inflammation and insulin resistance in obesity","volume":"126","author":"Wu","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.peptides.2024.171210_bib32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/CIRCRESAHA.117.309715","article-title":"Gut microbiota in cardiovascular health and disease","volume":"120","author":"Tang","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.peptides.2024.171210_bib33","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.peptides.2024.171210_bib34","doi-asserted-by":"crossref","first-page":"E77","DOI":"10.1152\/ajpendo.1997.273.1.E77","article-title":"Intestinal growth-promoting properties of glucagon-like peptide-2 in mice","volume":"273","author":"Tsai","year":"1997","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib35","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1111\/bph.15278","article-title":"Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function","volume":"178","author":"Ejarque","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2024.171210_bib36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000363025","article-title":"GLP-2 suppresses LPS-induced inflammation in macrophages by inhibiting ERK phosphorylation and NF-\u03baB activation","volume":"34","author":"Xie","year":"2014","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.peptides.2024.171210_bib37","article-title":"GLP-2 Attenuates LPS-Induced Inflammation in BV-2 Cells by Inhibiting ERK1\/2, JNK1\/2 and NF-\u03baB Signaling Pathways","volume":"17","author":"Li","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2024.171210_bib38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.nbd.2018.10.012","article-title":"Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain","volume":"121","author":"Nuzzo","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.peptides.2024.171210_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MED.0000000000000120","article-title":"Gut hormones in the treatment of short-bowel syndrome and intestinal failure","volume":"22","author":"Jeppesen","year":"2015","journal-title":"Curr. Opin. Endocrinol., Diabetes Obes."},{"key":"10.1016\/j.peptides.2024.171210_bib40","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/jpen.1767","article-title":"Effect of glepaglutide, a long-acting glucagon-like peptide-2 analog, on gastrointestinal transit time and motility in patients with short bowel syndrome: findings from a randomized trial","volume":"44","author":"Hvistendahl","year":"2020","journal-title":"J. Parenter. Enter. Nutr."},{"key":"10.1016\/j.peptides.2024.171210_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.119.262238","article-title":"Pharmacological characterization of apraglutide, a novel long-acting peptidic glucagon-like peptide-2 agonist, for the treatment of short bowel syndrome","volume":"373","author":"Hargrove","year":"2020","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.peptides.2024.171210_bib42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clnesp.2022.09.552","article-title":"An ongoing phase 2 study of Hm15912, a novel long-acting glucagon-like peptide 2(Glp-2) analog for short bowel syndrome-intestinal failure (Sbs-If) patients","volume":"54","author":"Kim","year":"2023","journal-title":"Clin. Nutr. ESPEN"},{"key":"10.1016\/j.peptides.2024.171210_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/apt.12092","article-title":"Review article: a comparison of glucagon-like peptides 1 and 2","volume":"37","author":"Janssen","year":"2013","journal-title":"Aliment Pharm. Ther."},{"key":"10.1016\/j.peptides.2024.171210_bib44","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/gast.2000.16489","article-title":"Enteroendocrine localization of GLP-2 receptor expression in humans and rodents","volume":"119","author":"Yusta","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2024.171210_bib45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1196\/annals.1317.006","article-title":"The glucagon-like peptides","volume":"1070","author":"Brubaker","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.peptides.2024.171210_bib46","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/metabo12050420","article-title":"The sensory mechanisms of nutrient-induced GLP-1 secretion","volume":"12","author":"Hj\u00f8rne","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.peptides.2024.171210_bib47","first-page":"2884","article-title":"In vivo and in vitro degradation of glucagon-like peptide-2 in humans1","volume":"85","author":"Hartmann","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib48","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1210\/endo.138.11.5482","article-title":"Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2","volume":"138","author":"Brubaker","year":"1997","journal-title":"Endocrinol. (Phila.)"},{"key":"10.1016\/j.peptides.2024.171210_bib49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","article-title":"Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2","volume":"76","author":"Drucker","year":"2014","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.peptides.2024.171210_bib50","doi-asserted-by":"crossref","first-page":"8888","DOI":"10.1021\/bi000497p","article-title":"Structural determinants for activity of glucagon-like peptide-2","volume":"39","author":"DaCambra","year":"2000","journal-title":"Biochem. (Easton)"},{"key":"10.1016\/j.peptides.2024.171210_bib51","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/bph.15766","article-title":"Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology","volume":"179","author":"Gadgaard","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2024.171210_bib52","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1073\/pnas.96.4.1569","article-title":"Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2","volume":"96","author":"Munroe","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.peptides.2024.171210_bib53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molmet.2017.03.006","article-title":"Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway","volume":"6","author":"Yusta","year":"2017","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib54","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00125-007-0761-6","article-title":"The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas","volume":"50","author":"de Heer","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2024.171210_bib55","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.numecd.2010.07.014","article-title":"Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart","volume":"22","author":"Angelone","year":"2012","journal-title":"Nutr., Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.peptides.2024.171210_bib56","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1210\/en.2019-00398","article-title":"Localization of glucagon-like peptide-2 receptor expression in the mouse","volume":"160","author":"Yusta","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2024.171210_bib57","doi-asserted-by":"crossref","first-page":"35345","DOI":"10.1074\/jbc.M005510200","article-title":"The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway","volume":"275","author":"Yusta","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2024.171210_bib58","doi-asserted-by":"crossref","first-page":"24896","DOI":"10.1074\/jbc.M201358200","article-title":"Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein Kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-Kinase","volume":"277","author":"Yusta","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2024.171210_bib59","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1152\/ajpendo.00585.2009","article-title":"GLP-2 potentiates L-type Ca2+ channel activity associated with stimulated glucose uptake in hippocampal neurons","volume":"298","author":"Wang","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib60","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cmet.2013.06.014","article-title":"Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons","volume":"18","author":"Shi","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105627","article-title":"Impact of intestinal disorders on central and peripheral nervous system diseases","volume":"165","author":"El-Hakim","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.peptides.2024.171210_bib62","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","article-title":"Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD","volume":"45","author":"Henriksen","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.peptides.2024.171210_bib63","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1091\/mbc.e03-11-0825","article-title":"Lipid raft-dependent glucagon-like peptide-2 receptor trafficking occurs independently of agonist-induced desensitization","volume":"15","author":"Estall","year":"2004","journal-title":"MBoC"},{"key":"10.1016\/j.peptides.2024.171210_bib64","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/bph.16040","article-title":"Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice","volume":"180","author":"Gabe","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2024.171210_bib65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/dom.15288","article-title":"Abolishing \u03b2-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists","volume":"26","author":"Hinds","year":"2024","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib66","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/gast.2001.22555","article-title":"Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon","volume":"120","author":"Jeppesen","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2024.171210_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gut.47.1.112","article-title":"Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse","volume":"47","author":"Benjamin","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.peptides.2024.171210_bib68","doi-asserted-by":"crossref","first-page":"G1249","DOI":"10.1152\/ajpgi.2000.279.6.G1249","article-title":"GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis","volume":"279","author":"Burrin","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.peptides.2024.171210_bib69","doi-asserted-by":"crossref","first-page":"G518","DOI":"10.1152\/ajpgi.00024.2006","article-title":"Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis","volume":"292","author":"Brun","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.peptides.2024.171210_bib70","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/gut.2008.165886","article-title":"Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability","volume":"58","author":"Cani","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.peptides.2024.171210_bib71","series-title":"StatPearls","article-title":"Biochemistry, Lipopolysaccharide","author":"Farhana","year":"2024"},{"key":"10.1016\/j.peptides.2024.171210_bib72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41569-022-00737-2","article-title":"Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease","volume":"20","author":"Violi","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.peptides.2024.171210_bib73","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.pneurobio.2010.07.003","article-title":"Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides","volume":"92","author":"Vrang","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.peptides.2024.171210_bib74","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/en.2004-0100","article-title":"Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells","volume":"145","author":"Lovshin","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2024.171210_bib75","doi-asserted-by":"crossref","first-page":"G211","DOI":"10.1152\/ajpgi.00530.2006","article-title":"Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2","volume":"293","author":"Sigalet","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.peptides.2024.171210_bib76","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bcp.2006.04.011","article-title":"NF-\u03baB activation by reactive oxygen species: fifteen years later","volume":"72","author":"Gloire","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.peptides.2024.171210_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021891","article-title":"Gastrodin inhibits expression of inducible NO synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured LPS-stimulated microglia via MAPK pathways","volume":"6","author":"Dai","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.peptides.2024.171210_bib78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.peptides.2024.171210_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.pathol.2.010506.091859","article-title":"Endocrine functions of adipose tissue","volume":"2","author":"Waki","year":"2007","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.peptides.2024.171210_bib80","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am. J. Physiol. -Cell Physiol."},{"key":"10.1016\/j.peptides.2024.171210_bib81","doi-asserted-by":"crossref","first-page":"E853","DOI":"10.1152\/ajpendo.00245.2012","article-title":"GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility","volume":"303","author":"Guan","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib82","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/77535","article-title":"The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake","volume":"6","author":"Tang-Christensen","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.peptides.2024.171210_bib83","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.brainres.2007.02.043","article-title":"Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei","volume":"1149","author":"Vrang","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.peptides.2024.171210_bib84","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2147\/DMSO.S375559","article-title":"The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors","volume":"15","author":"Dong","year":"2022","journal-title":"DMSO"},{"key":"10.1016\/j.peptides.2024.171210_bib85","doi-asserted-by":"crossref","first-page":"21489","DOI":"10.1074\/jbc.M009382200","article-title":"Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling","volume":"276","author":"Lovshin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2024.171210_bib86","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/sj.ijo.0801912","article-title":"Glucagon-like peptide containing pathways in the regulation of feeding behaviour","volume":"25","author":"Tang-Christensen","year":"2001","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2024.171210_bib87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0167-0115(03)00175-7","article-title":"Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety","volume":"116","author":"Schmidt","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2024.171210_bib88","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.ijo.0802247","article-title":"No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects","volume":"27","author":"S\u00f8rensen","year":"2003","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.peptides.2024.171210_bib89","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000257","article-title":"Glucagon-like peptide 2 inhibits postprandial gallbladder emptying in man: a randomized, double-blinded, crossover study","volume":"11","author":"Hansen","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.peptides.2024.171210_bib90","article-title":"Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function","volume":"2009","author":"Jeppesen","year":"2009","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.peptides.2024.171210_bib91","first-page":"G1038","article-title":"Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon","volume":"299","author":"Amato","year":"2010","journal-title":"Am. J. Physiol.: Gastrointest. Liver Physiol."},{"key":"10.1016\/j.peptides.2024.171210_bib92","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/00365520410004424","article-title":"Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1","volume":"39","author":"Nagell","year":"2004","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.peptides.2024.171210_bib93","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1365-2036.2011.04609.x","article-title":"Review article: the role of gastric motility in the control of food intake","volume":"33","author":"Janssen","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.peptides.2024.171210_bib94","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1467-789X.2011.00901.x","article-title":"The effects of weight loss strategies on gastric emptying and appetite control","volume":"12","author":"Horner","year":"2011","journal-title":"Obes. Rev."},{"key":"10.1016\/j.peptides.2024.171210_bib95","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2005.10.004","article-title":"Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans","volume":"130","author":"Meier","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2024.171210_bib96","first-page":"1","article-title":"Effects of exogenous GIP and GLP-2 on bone turnover in individuals with type 2 diabetes","volume":"00","author":"Skov-Jeppesen","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib97","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.regpep.2011.03.003","article-title":"The effect oF Glucagon-like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients","volume":"168","author":"Bremholm","year":"2011","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2024.171210_bib98","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.regpep.2012.10.002","article-title":"Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients","volume":"180","author":"H\u00f8yerup","year":"2013","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2024.171210_bib99","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0016-5085(03)00667-X","article-title":"GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets","volume":"125","author":"Guan","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2024.171210_bib100","doi-asserted-by":"crossref","first-page":"E1050","DOI":"10.1152\/ajpendo.1997.272.6.E1050","article-title":"Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2","volume":"272","author":"Brubaker","year":"1997","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/bj20020393","article-title":"Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2","volume":"367","author":"Au","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.peptides.2024.171210_bib102","doi-asserted-by":"crossref","first-page":"R1965","DOI":"10.1152\/ajpregu.1997.273.6.R1965","article-title":"Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo","volume":"273","author":"Cheeseman","year":"1997","journal-title":"Am. J. Physiol. Regul.\u00a0Integr. Comp. Physiol."},{"key":"10.1016\/j.peptides.2024.171210_bib103","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3382\/ps.2009-00547","article-title":"The effect of glucagon-like peptide 2 injection on performance, small intestinal morphology, and nutrient transporter expression of stressed broiler chickens1","volume":"89","author":"Hu","year":"2010","journal-title":"Poult. Sci."},{"key":"10.1016\/j.peptides.2024.171210_bib104","doi-asserted-by":"crossref","first-page":"R1986","DOI":"10.1152\/ajpregu.2001.281.6.R1986","article-title":"GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs","volume":"281","author":"Petersen","year":"2001","journal-title":"Am. J. Physiol. Regul.\u00a0Integr. Comp. Physiol."},{"key":"10.1016\/j.peptides.2024.171210_bib105","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1203\/00006450-200210000-00007","article-title":"Glucagon-like peptide 2 enhances maltase-glucoamylase and sucrase-isomaltase gene expression and activity in parenterally fed premature neonatal piglets","volume":"52","author":"Petersen","year":"2002","journal-title":"Pedia Res."},{"key":"10.1016\/j.peptides.2024.171210_bib106","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.molmet.2017.01.005","article-title":"Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport","volume":"6","author":"Lee","year":"2017","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib107","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2009.05.051","article-title":"Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36","volume":"137","author":"Hsieh","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2024.171210_bib108","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2014.08.037","article-title":"Glucagon-like peptide-2 regulates release of chylomicrons from the intestine","volume":"147","author":"Dash","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.peptides.2024.171210_bib109","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/dom.13839","article-title":"Glucagon-like peptide-2 mobilizes lipids from the intestine by a systemic nitric oxide-independent mechanism","volume":"21","author":"Xiao","year":"2019","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib110","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1210\/clinem\/dgac690","article-title":"Glucagon-like peptide-2 acutely enhances chylomicron secretion in humans without mobilizing cytoplasmic lipid droplets","volume":"108","author":"Syed-Abdul","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2024.171210_bib111","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/07435800.2016.1141950","article-title":"Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet","volume":"41","author":"Baldassano","year":"2016","journal-title":"Endocr. Res."},{"key":"10.1016\/j.peptides.2024.171210_bib112","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2024.171210_bib113","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136907","article-title":"Loss of Glp2r signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice","volume":"5","author":"Fuchs","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.peptides.2024.171210_bib114","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.peptides.2024.171210_bib115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.peptides.2024.171210_bib116","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.3748\/wjg.v28.i44.6258","article-title":"Glucagon-like peptide-2 analogues for Crohn\u2019s disease patients with short bowel syndrome and intestinal failure","volume":"28","author":"Pizzoferrato","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.peptides.2024.171210_bib117","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/17474124.2021.1913052","article-title":"Teduglutide for pediatric short bowel syndrome patients","volume":"15","author":"Rosete","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2024.171210_bib118","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ebiom.2019.07.016","article-title":"Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial","volume":"46","author":"Naimi","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.peptides.2024.171210_bib119","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/17474124.2018.1417032","article-title":"Glucagon like peptide-2 and neoplasia; a systematic review","volume":"12","author":"Ring","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.peptides.2024.171210_bib120","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/gut.2003.035212","article-title":"Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice","volume":"53","author":"Thulesen","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.peptides.2024.171210_bib121","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ajcnut.2023.02.015","article-title":"Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring","volume":"117","author":"de Dreuille","year":"2023","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.peptides.2024.171210_bib122","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jpen.1982","article-title":"De novo development of distal jejunal and duodenal adenomas after 41 months of teduglutide treatment in a patient with short-bowel syndrome: a case report","volume":"45","author":"Pevny","year":"2021","journal-title":"J. Parenter. Enter. Nutr."},{"key":"10.1016\/j.peptides.2024.171210_bib123","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.clcc.2019.02.006","article-title":"Accelerated colorectal polyposis in an immunosuppressed patient with a small bowel transplant treated with teduglutide: case report and review of literature","volume":"18","author":"George","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.peptides.2024.171210_bib124","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820905766","article-title":"Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials","volume":"13","author":"Pape","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.peptides.2024.171210_bib125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000503043","article-title":"GLP-2 Analogues as first specific treatment of intestinal failure","volume":"35","author":"Blumenstein","year":"2019","journal-title":"Visc. Med."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978124000639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978124000639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:36:13Z","timestamp":1717115773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978124000639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":125,"alternative-id":["S0196978124000639"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2024.171210","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the GLP-2 receptor in the management of obesity","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2024.171210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"171210"}}